Close Menu

NEW YORK – CStone Pharmaceuticals and Blueprint Medicines said Monday that they dosed their first patient in a Phase Ib/II trial investigating fisogatinib (BLU-554) in combination with CStone's PD-L1 inhibitor CS1001 to treat FGFR4-driven, locally advanced or metastatic hepatocellular carcinoma (HCC). 

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.